NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Accent Therapeutics

Accent Therapeutics

Private
Lexington, MassachusettsHealthcare & Life Scienceshttps://accenttx.com/

Last Round

Series C

Jan 23, 2024

Total Funding Raised

$178M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Accent Therapeutics is a biopharmaceutical company that develops small molecule precision oncology therapies targeting RNA-modifying proteins.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

oncology therapeuticssmall molecule inhibitorRNA-modifying proteinsdrug discoverybiotechclinical trialscancer researchprecision medicinebiopharmatherapeutic pipelinedrug developmentRNA therapeuticspreclinical databiomarker discoverydrug licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Accent Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Accent Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Accent Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJan 23, 2024
Series BApr 23, 2020
Series ASep 18, 2017

Key People

Founding team and executive leadership

Shakti Narayan

Chief Executive Officer

Executive Team

Accent Therapeutics Investors

Notable investors and investment history

Accent Therapeutics investors
InvestorRounds
EcoR1 CapitalSeries C, Series A, Series B
The Column GroupSeries A, Series B, Series C
GVSeries B, Series C
Mirae AssetSeries C
Droia VenturesSeries B, Series C
The Chernin GroupSeries B, Series C, Series A
AbbVie VenturesSeries B, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    New data for KIF18A inhibitor ATX-295 presented at AACR Annual Meeting.

  • Apr 17, 2026

    Presented at the AACR Annual Meeting 2026 in San Diego.

Accent Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Accent Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Accent Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLexington, Massachusetts
Employee Range31
Year Founded2017
Last FundingJan 23, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.